US4894326A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibody defining oncofetal structure of fibronectin
Assignee: Fred Hutchinson Cancer Center
•
Filing: 1986-04-09
•
Granted: 1990-01-16
•
Expires: 2006-04-09
Abstract
Abstract Antibody defining structure present in fibronectins from tumors and fetal tissues but absent in fibronectins from normal adult tissues and plasma; useful for diagnosing and treating human cancers.
Inventors
- 👤 Hidemitsu Matsuura
- 👤 Sen-itiroh Hakomori
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-30 16:54
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/5757; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/81; Y10S435/8215; Y10S435/948; Y10S435/975; Y10S436/00; Y10S436/811; Y10S436/813; Y10S530/00; Y10S530/808; Y10S530/809
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
40 words
An immunological binding partner defined by specifically binding with the COOH-terminal region released by cathepsin D digestion of oncofetal fibronectin but not with either normal adult fibronectin or the Hep-2 or Fib-2 fragments released by thermolysin digestion of oncofetal fibronectin.
Claim 2
Dependent Claim
40 words
An immunological binding partner defined by specifically binding with the COOH-terminal region released by cathepsin D digestion of oncofetal fibronectin but not with either normal adult fibronectin or the Hep-2 or Fib-2 fragments released by thermolysin digestion of oncofetal fibronectin.
Claim 3
Dependent Claim
24 words
A test kit useful for assaying the presence of oncofetal fibronectin, comprising one or more containers containing the immunological binding partner of claim 1.
Claim 4
Dependent Claim
17 words
The test kit of claim 2 wherein the immunological binding partner is coupled to a detectable marker.
Claim 5
Dependent Claim
12 words
The immunological binding partner of claim 1 coupled to a detectable marker.
Claim 6
Dependent Claim
28 words
The composition of claim 4 wherein the detectable marker is selected from the group consisting of enzymes, chromophores, fluorophores, coenzymes, chemiluminescent materials, enzyme inhibitors, paramagnetic metals, and radionuclides.
Claim 7
Dependent Claim
36 words
A method of immunological detection of cells expressing oncofetal fibronectin comprising the steps of reacting biopsied cells with the composition of claim 4 and detecting detectable marker coupled to reacted immunological binding partner on the cells.
Claim 8
Dependent Claim
11 words
The method of claim 6, wherein the cells are fetal cells.
Claim 9
Dependent Claim
11 words
The method of claim 6 wherein the cells are tumor cells.
Claim 10
Dependent Claim
19 words
The method of claim 8 wherein the cells are selected from the group consisting of carcinoma and sarcoma cells.
Claim 11
Dependent Claim
12 words
The method of claim 9 wherein the carcinoma cells are hepatoma cells.
Claim 12
Dependent Claim
46 words
A hybridoma cell line capable of producing a monoclonal antibody capable of specifically binding with the COOH-terminal region released by cathepsin D digestion of oncofetal fibronectin but not with either normal adult fibronectin or the Hep-2 or Fib-2 fragments released by thermolysin digestion of oncofetal fibronectin.
Claim 13
Dependent Claim
46 words
A hybridoma cell line capable of producing a monoclonal antibody capable of specifically binding with the COOH-terminal region released by cathepsin D digestion of oncofetal fibronectin but not with either normal adult fibronectin or the Hep-2 or Fib-2 fragments released by thermolysin digestion of oncofetal fibronectin.
Claim 14
Dependent Claim
10 words
Hybridoma cell line ATCC No. HB9018 according to claim 11.
Claim 15
Dependent Claim
13 words
A monoclonal antibody produced by the hybridoma a cell line of claim 11.
Claim 16
Dependent Claim
10 words
The monoclonal antibody of claim 13 coupled to a radionuclide.
Claim 17
Dependent Claim
45 words
In a method of detecting tumor-associated antigen in blood serum including the steps of contacting the serium with antibody directed to tumor-associated antigen and detecting any reaction between the antibody and serum antigen, the improvement comprising contacting the serum with the antibody of claim 13.
Claim 18
Dependent Claim
23 words
A test kit useful for assaying the presence of oncofetal fibronectin, comprising one or more containers containing the monoclonal antibody of claim 13.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-01-15 | 1993-07-17 | 1994-01-16 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-01-15 | 1997-07-17 | 1998-01-16 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-01-15 | 2001-07-17 | 2002-01-16 | $7700.00 | Window Closed / Lapsed |